Oxford BioMedica plc using EPIC/TICKER code (LON:OXB) has had its stock rating noted as “Reiterates” with the recommendation being set at “HOLD” this morning by analysts at N+1 Singer. The brokerage now has a “hold” rating on the biopharmaceutical company’s stock. The brokerage presently has a $0.25 price target on the stock.
Several other research analysts also recently commented on OXB. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 13 ($0.17) target price on shares of Oxford BioMedica plc in a research note on Thursday.
The stock’s 50 day moving average is 8.87 and its 200 day moving average is 6.08. Shore Capital restated a “not rated” rating on shares of Oxford BioMedica plc in a research report on Thursday, July 13th. The stock’s market cap is GBX 305.74 million.
The share price of the company (LON:OXB) was up +10.74% during the last trading session, with a high of 10.25 during the day and the volume of Oxford Biomedica shares traded was 7036601.
According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases”. If you are viewing this news story on another website, it was illegally copied and republished in violation of USA & worldwide copyright & trademark laws. This is indicating the analyst believes there is a potential downside of -5.1% from today’s opening price of 10.75 GBX. The stock was bought at an average cost of GBX 9 ($0.12) per share, with a total value of £59,400 ($76,823.59). The stock was acquired at an average price of GBX 8 ($0.10) per share, with a total value of £19,974.96 ($25,834.14).
Oxford BioMedica is the manufacturer of the lentiviral vector that encodes CTL019, and inked a deal with Novartis in July 2017 for the commercial and clinical supply of lentiviral vectors used to generate CTL019 and other undisclosed CAR-T products. The company operates through Partnering and R&D segments. The Company is engaged in lentiviral vector and cell therapy research, development and production.